Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 4942 | 417716-92-8 |
Dose | Unit | Route |
---|---|---|
18 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 26, 2015 | PMDA | Eisai Co., Ltd. | |
Feb. 13, 2015 | FDA | EISAI INC | |
May 28, 2015 | EMA | Eisai Europe Ltd |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypertension | 1274.04 | 24.88 | 768 | 12954 | 243510 | 56034835 |
Malignant neoplasm progression | 1097.02 | 24.88 | 472 | 13250 | 73115 | 56205230 |
Proteinuria | 716.42 | 24.88 | 236 | 13486 | 17334 | 56261011 |
Palmar-plantar erythrodysaesthesia syndrome | 506.10 | 24.88 | 191 | 13531 | 20874 | 56257471 |
Hypothyroidism | 496.23 | 24.88 | 223 | 13499 | 37973 | 56240372 |
Decreased appetite | 483.54 | 24.88 | 410 | 13312 | 218821 | 56059524 |
Platelet count decreased | 395.44 | 24.88 | 272 | 13450 | 106111 | 56172234 |
Diarrhoea | 245.96 | 24.88 | 502 | 13220 | 638005 | 55640340 |
Hepatic encephalopathy | 236.55 | 24.88 | 90 | 13632 | 10020 | 56268325 |
Immune-mediated hypothyroidism | 173.50 | 24.88 | 31 | 13691 | 143 | 56278202 |
Blood pressure increased | 165.59 | 24.88 | 190 | 13532 | 144986 | 56133359 |
Cholecystitis | 137.05 | 24.88 | 68 | 13654 | 14367 | 56263978 |
Dysphonia | 136.27 | 24.88 | 99 | 13623 | 41848 | 56236497 |
Drug ineffective | 133.08 | 24.88 | 31 | 13691 | 918958 | 55359387 |
Malaise | 115.15 | 24.88 | 267 | 13455 | 367593 | 55910752 |
Blood thyroid stimulating hormone increased | 106.82 | 24.88 | 45 | 13677 | 6518 | 56271827 |
Hepatic function abnormal | 106.44 | 24.88 | 79 | 13643 | 34479 | 56243866 |
Gastrointestinal perforation | 98.97 | 24.88 | 35 | 13687 | 3164 | 56275181 |
Stomatitis | 97.36 | 24.88 | 133 | 13589 | 120677 | 56157668 |
Tumour haemorrhage | 94.54 | 24.88 | 28 | 13694 | 1436 | 56276909 |
Hyperthyroidism | 92.68 | 24.88 | 51 | 13671 | 13301 | 56265044 |
Fistula | 84.88 | 24.88 | 42 | 13680 | 8813 | 56269532 |
Rheumatoid arthritis | 80.25 | 24.88 | 3 | 13719 | 382601 | 55895744 |
Pneumothorax | 77.13 | 24.88 | 47 | 13675 | 14820 | 56263525 |
Pyrexia | 75.00 | 24.88 | 248 | 13474 | 418525 | 55859820 |
Ascites | 73.67 | 24.88 | 66 | 13656 | 37478 | 56240867 |
Tracheal fistula | 65.53 | 24.88 | 11 | 13711 | 32 | 56278313 |
Fatigue | 65.03 | 24.88 | 369 | 13353 | 788183 | 55490162 |
Renal impairment | 63.67 | 24.88 | 88 | 13634 | 80625 | 56197720 |
Thrombocytopenia | 62.56 | 24.88 | 116 | 13606 | 136108 | 56142237 |
Condition aggravated | 62.46 | 24.88 | 6 | 13716 | 344892 | 55933453 |
Cerebral haemorrhage | 55.54 | 24.88 | 50 | 13672 | 28556 | 56249789 |
Immune-mediated hepatic disorder | 54.91 | 24.88 | 13 | 13709 | 276 | 56278069 |
Posterior reversible encephalopathy syndrome | 54.83 | 24.88 | 39 | 13683 | 15921 | 56262424 |
Cardiac failure | 53.81 | 24.88 | 82 | 13640 | 82011 | 56196334 |
Drug hypersensitivity | 51.95 | 24.88 | 4 | 13718 | 275201 | 56003144 |
Dehydration | 51.33 | 24.88 | 117 | 13605 | 158708 | 56119637 |
Hypersensitivity | 50.52 | 24.88 | 3 | 13719 | 256405 | 56021940 |
Intestinal perforation | 50.16 | 24.88 | 32 | 13690 | 10927 | 56267418 |
Protein urine present | 48.76 | 24.88 | 25 | 13697 | 5651 | 56272694 |
Colitis | 47.98 | 24.88 | 55 | 13667 | 41756 | 56236589 |
Weight decreased | 46.97 | 24.88 | 147 | 13575 | 240567 | 56037778 |
Large intestine perforation | 46.40 | 24.88 | 27 | 13695 | 7824 | 56270521 |
Oral pain | 45.31 | 24.88 | 43 | 13679 | 26250 | 56252095 |
Cholecystitis acute | 45.15 | 24.88 | 26 | 13696 | 7390 | 56270955 |
Nephrotic syndrome | 44.53 | 24.88 | 23 | 13699 | 5277 | 56273068 |
Swelling | 43.83 | 24.88 | 4 | 13718 | 239767 | 56038578 |
Arterial haemorrhage | 43.58 | 24.88 | 16 | 13706 | 1609 | 56276736 |
Thyroid disorder | 43.19 | 24.88 | 32 | 13690 | 13906 | 56264439 |
Immune-mediated hepatitis | 42.15 | 24.88 | 14 | 13708 | 1047 | 56277298 |
Weight increased | 41.54 | 24.88 | 4 | 13718 | 229699 | 56048646 |
Pain | 40.61 | 24.88 | 62 | 13660 | 663122 | 55615223 |
Oesophageal fistula | 40.30 | 24.88 | 9 | 13713 | 146 | 56278199 |
Infusion related reaction | 39.52 | 24.88 | 3 | 13719 | 208928 | 56069417 |
Off label use | 39.07 | 24.88 | 47 | 13675 | 556133 | 55722212 |
Myocarditis | 38.41 | 24.88 | 25 | 13697 | 8833 | 56269512 |
Vomiting | 38.11 | 24.88 | 229 | 13493 | 497999 | 55780346 |
Toxicity to various agents | 37.87 | 24.88 | 5 | 13717 | 224559 | 56053786 |
Thyroiditis | 36.52 | 24.88 | 15 | 13707 | 2037 | 56276308 |
Tracheal haemorrhage | 34.53 | 24.88 | 8 | 13714 | 154 | 56278191 |
Female genital tract fistula | 33.50 | 24.88 | 18 | 13704 | 4474 | 56273871 |
Epistaxis | 33.16 | 24.88 | 59 | 13663 | 66964 | 56211381 |
Arthropathy | 32.50 | 24.88 | 5 | 13717 | 200270 | 56078075 |
Hypertensive crisis | 32.22 | 24.88 | 27 | 13695 | 14009 | 56264336 |
Hyponatraemia | 31.59 | 24.88 | 74 | 13648 | 102065 | 56176280 |
Joint swelling | 30.99 | 24.88 | 16 | 13706 | 289784 | 55988561 |
Peritonitis | 30.81 | 24.88 | 28 | 13694 | 16174 | 56262171 |
Nausea | 30.21 | 24.88 | 301 | 13421 | 763877 | 55514468 |
Drug intolerance | 29.25 | 24.88 | 14 | 13708 | 264804 | 56013541 |
Fall | 28.64 | 24.88 | 27 | 13695 | 357483 | 55920862 |
Eastern Cooperative Oncology Group performance status worsened | 28.49 | 24.88 | 10 | 13712 | 883 | 56277462 |
Renal cancer | 28.17 | 24.88 | 17 | 13705 | 5262 | 56273083 |
Sinusitis | 27.72 | 24.88 | 7 | 13715 | 197574 | 56080771 |
Alopecia | 27.45 | 24.88 | 19 | 13703 | 293439 | 55984906 |
Product dose omission issue | 27.33 | 24.88 | 8 | 13714 | 204745 | 56073600 |
Taste disorder | 27.21 | 24.88 | 21 | 13701 | 9694 | 56268651 |
Primary adrenal insufficiency | 25.23 | 24.88 | 6 | 13716 | 130 | 56278215 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Decreased appetite | 765.61 | 22.32 | 608 | 14434 | 152609 | 31529693 |
Hepatic encephalopathy | 741.77 | 22.32 | 269 | 14773 | 13402 | 31668900 |
Malignant neoplasm progression | 736.80 | 22.32 | 460 | 14582 | 78538 | 31603764 |
Proteinuria | 560.16 | 22.32 | 232 | 14810 | 16531 | 31665771 |
Palmar-plantar erythrodysaesthesia syndrome | 546.96 | 22.32 | 223 | 14819 | 15260 | 31667042 |
Hypertension | 530.96 | 22.32 | 457 | 14585 | 127643 | 31554659 |
Diarrhoea | 369.28 | 22.32 | 622 | 14420 | 351787 | 31330515 |
Hypothyroidism | 278.02 | 22.32 | 146 | 14896 | 17801 | 31664501 |
Tumour haemorrhage | 221.43 | 22.32 | 72 | 14970 | 2556 | 31679746 |
Liver carcinoma ruptured | 183.54 | 22.32 | 36 | 15006 | 135 | 31682167 |
Fatigue | 160.17 | 22.32 | 431 | 14611 | 334775 | 31347527 |
Dysphonia | 142.61 | 22.32 | 100 | 14942 | 20491 | 31661811 |
Blood pressure increased | 137.86 | 22.32 | 179 | 14863 | 79454 | 31602848 |
Malaise | 132.41 | 22.32 | 264 | 14778 | 168247 | 31514055 |
Oesophageal varices haemorrhage | 124.59 | 22.32 | 48 | 14994 | 2812 | 31679490 |
Ascites | 112.64 | 22.32 | 117 | 14925 | 40896 | 31641406 |
Cholecystitis | 105.85 | 22.32 | 63 | 14979 | 9754 | 31672548 |
Drug ineffective | 103.54 | 22.32 | 30 | 15012 | 395543 | 31286759 |
Hepatic failure | 98.35 | 22.32 | 98 | 14944 | 32604 | 31649698 |
Ammonia increased | 94.95 | 22.32 | 44 | 14998 | 4083 | 31678219 |
Stomatitis | 93.32 | 22.32 | 104 | 14938 | 39334 | 31642968 |
Hepatic function abnormal | 87.89 | 22.32 | 103 | 14939 | 41119 | 31641183 |
Cholangitis | 82.85 | 22.32 | 50 | 14992 | 7936 | 31674366 |
Pneumothorax | 77.02 | 22.32 | 64 | 14978 | 16846 | 31665456 |
Blood bilirubin increased | 75.23 | 22.32 | 88 | 14954 | 35048 | 31647254 |
Blood thyroid stimulating hormone increased | 67.01 | 22.32 | 33 | 15009 | 3504 | 31678798 |
Dehydration | 64.41 | 22.32 | 161 | 14881 | 118950 | 31563352 |
Oral pain | 64.27 | 22.32 | 46 | 14996 | 9719 | 31672583 |
Tumour rupture | 58.27 | 22.32 | 15 | 15027 | 226 | 31682076 |
Tracheal fistula | 54.81 | 22.32 | 12 | 15030 | 85 | 31682217 |
Drug interaction | 54.04 | 22.32 | 16 | 15026 | 208527 | 31473775 |
Toxicity to various agents | 52.68 | 22.32 | 11 | 15031 | 181476 | 31500826 |
Condition aggravated | 51.79 | 22.32 | 8 | 15034 | 164001 | 31518301 |
Epistaxis | 50.45 | 22.32 | 91 | 14951 | 53616 | 31628686 |
Platelet count decreased | 50.23 | 22.32 | 140 | 14902 | 110295 | 31572007 |
Off label use | 48.75 | 22.32 | 56 | 14986 | 347218 | 31335084 |
Portal vein thrombosis | 47.15 | 22.32 | 26 | 15016 | 3481 | 31678821 |
Weight decreased | 45.74 | 22.32 | 173 | 14869 | 159779 | 31522523 |
Gastrointestinal perforation | 43.60 | 22.32 | 25 | 15017 | 3607 | 31678695 |
Hyperammonaemia | 41.92 | 22.32 | 29 | 15013 | 5804 | 31676498 |
Vomiting | 41.74 | 22.32 | 213 | 14829 | 223760 | 31458542 |
Renal cancer | 41.20 | 22.32 | 32 | 15010 | 7647 | 31674655 |
Cholecystitis acute | 37.90 | 22.32 | 27 | 15015 | 5660 | 31676642 |
Immune-mediated hepatitis | 35.16 | 22.32 | 17 | 15025 | 1733 | 31680569 |
Thyroiditis | 34.75 | 22.32 | 18 | 15024 | 2125 | 31680177 |
Adrenal insufficiency | 34.50 | 22.32 | 36 | 15006 | 12623 | 31669679 |
Interstitial lung disease | 33.12 | 22.32 | 83 | 14959 | 61320 | 31620982 |
Tracheo-oesophageal fistula | 32.75 | 22.32 | 11 | 15031 | 432 | 31681870 |
Completed suicide | 32.47 | 22.32 | 3 | 15039 | 91511 | 31590791 |
Protein urine present | 31.96 | 22.32 | 23 | 15019 | 4897 | 31677405 |
Pneumonitis | 31.43 | 22.32 | 54 | 14988 | 30598 | 31651704 |
Taste disorder | 31.30 | 22.32 | 24 | 15018 | 5626 | 31676676 |
Rhythm idioventricular | 28.89 | 22.32 | 9 | 15033 | 277 | 31682025 |
Liver abscess | 28.72 | 22.32 | 19 | 15023 | 3532 | 31678770 |
Nausea | 28.06 | 22.32 | 245 | 14797 | 307702 | 31374600 |
Neutropenia | 27.88 | 22.32 | 16 | 15026 | 140348 | 31541954 |
Arterial haemorrhage | 25.85 | 22.32 | 11 | 15031 | 833 | 31681469 |
Protein induced by vitamin K absence or antagonist II increased | 25.65 | 22.32 | 5 | 15037 | 18 | 31682284 |
Liver disorder | 24.95 | 22.32 | 48 | 14994 | 29659 | 31652643 |
Haemobilia | 23.70 | 22.32 | 8 | 15034 | 319 | 31681983 |
Cholangitis acute | 23.22 | 22.32 | 10 | 15032 | 780 | 31681522 |
Nephrotic syndrome | 22.92 | 22.32 | 22 | 15020 | 6981 | 31675321 |
Overdose | 22.81 | 22.32 | 6 | 15036 | 84658 | 31597644 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 1437.25 | 22.23 | 705 | 20322 | 121034 | 70786383 |
Hypertension | 1394.34 | 22.23 | 940 | 20087 | 295093 | 70612324 |
Proteinuria | 995.27 | 22.23 | 361 | 20666 | 29013 | 70878404 |
Decreased appetite | 872.19 | 22.23 | 719 | 20308 | 304061 | 70603356 |
Palmar-plantar erythrodysaesthesia syndrome | 803.03 | 22.23 | 311 | 20716 | 29936 | 70877481 |
Hepatic encephalopathy | 671.86 | 22.23 | 251 | 20776 | 21867 | 70885550 |
Hypothyroidism | 561.73 | 22.23 | 273 | 20754 | 45482 | 70861935 |
Diarrhoea | 375.21 | 22.23 | 756 | 20271 | 782585 | 70124832 |
Tumour haemorrhage | 294.25 | 22.23 | 87 | 20940 | 3635 | 70903782 |
Platelet count decreased | 277.03 | 22.23 | 301 | 20726 | 177921 | 70729496 |
Cholecystitis | 199.53 | 22.23 | 105 | 20922 | 20596 | 70886821 |
Drug ineffective | 187.77 | 22.23 | 28 | 20999 | 939724 | 69967693 |
Malaise | 168.97 | 22.23 | 386 | 20641 | 432546 | 70474871 |
Hepatic function abnormal | 165.61 | 22.23 | 147 | 20880 | 67849 | 70839568 |
Pneumothorax | 162.19 | 22.23 | 99 | 20928 | 25747 | 70881670 |
Dysphonia | 152.16 | 22.23 | 123 | 20904 | 49977 | 70857440 |
Immune-mediated hypothyroidism | 150.11 | 22.23 | 32 | 20995 | 334 | 70907083 |
Ascites | 141.05 | 22.23 | 134 | 20893 | 67413 | 70840004 |
Liver carcinoma ruptured | 135.86 | 22.23 | 26 | 21001 | 148 | 70907269 |
Blood pressure increased | 128.46 | 22.23 | 213 | 20814 | 188304 | 70719113 |
Blood thyroid stimulating hormone increased | 120.39 | 22.23 | 56 | 20971 | 8423 | 70898994 |
Oesophageal varices haemorrhage | 114.74 | 22.23 | 43 | 20984 | 3760 | 70903657 |
Tracheal fistula | 110.42 | 22.23 | 21 | 21006 | 115 | 70907302 |
Gastrointestinal perforation | 94.81 | 22.23 | 42 | 20985 | 5639 | 70901778 |
Blood bilirubin increased | 92.49 | 22.23 | 101 | 20926 | 59800 | 70847617 |
Condition aggravated | 89.20 | 22.23 | 11 | 21016 | 427624 | 70479793 |
Dehydration | 84.97 | 22.23 | 199 | 20828 | 225943 | 70681474 |
Fistula | 82.18 | 22.23 | 47 | 20980 | 10834 | 70896583 |
Stomatitis | 80.55 | 22.23 | 140 | 20887 | 128371 | 70779046 |
Cholecystitis acute | 80.53 | 22.23 | 48 | 20979 | 11946 | 70895471 |
Toxicity to various agents | 79.28 | 22.23 | 10 | 21017 | 382162 | 70525255 |
Immune-mediated hepatitis | 74.25 | 22.23 | 29 | 20998 | 2837 | 70904580 |
Hyperthyroidism | 73.27 | 22.23 | 55 | 20972 | 20036 | 70887381 |
Pyrexia | 73.21 | 22.23 | 364 | 20663 | 606588 | 70300829 |
Tracheo-oesophageal fistula | 71.37 | 22.23 | 19 | 21008 | 537 | 70906880 |
Fatigue | 69.52 | 22.23 | 449 | 20578 | 823870 | 70083547 |
Hepatic failure | 68.58 | 22.23 | 85 | 20942 | 57540 | 70849877 |
Arterial haemorrhage | 68.17 | 22.23 | 26 | 21001 | 2385 | 70905032 |
Nephrotic syndrome | 64.79 | 22.23 | 40 | 20987 | 10600 | 70896817 |
Cholangitis | 64.25 | 22.23 | 41 | 20986 | 11508 | 70895909 |
Ammonia increased | 62.55 | 22.23 | 34 | 20993 | 7104 | 70900313 |
Cerebral haemorrhage | 60.19 | 22.23 | 77 | 20950 | 53787 | 70853630 |
Renal impairment | 59.93 | 22.23 | 132 | 20895 | 143805 | 70763612 |
Large intestine perforation | 59.28 | 22.23 | 41 | 20986 | 13154 | 70894263 |
Off label use | 56.72 | 22.23 | 83 | 20944 | 742977 | 70164440 |
Weight increased | 56.40 | 22.23 | 4 | 21023 | 242327 | 70665090 |
Vomiting | 56.09 | 22.23 | 333 | 20694 | 592778 | 70314639 |
Hypersensitivity | 55.86 | 22.23 | 3 | 21024 | 229809 | 70677608 |
Drug interaction | 55.26 | 22.23 | 22 | 21005 | 381419 | 70525998 |
Oesophageal fistula | 53.67 | 22.23 | 14 | 21013 | 365 | 70907052 |
Thyroiditis | 52.20 | 22.23 | 25 | 21002 | 4011 | 70903406 |
Drug hypersensitivity | 51.73 | 22.23 | 8 | 21019 | 262451 | 70644966 |
Posterior reversible encephalopathy syndrome | 50.11 | 22.23 | 48 | 20979 | 24354 | 70883063 |
Intestinal perforation | 49.96 | 22.23 | 40 | 20987 | 16004 | 70891413 |
Cardiac failure | 49.20 | 22.23 | 122 | 20905 | 143419 | 70763998 |
Colitis | 48.68 | 22.23 | 76 | 20951 | 63738 | 70843679 |
Hyperammonaemia | 48.64 | 22.23 | 33 | 20994 | 10260 | 70897157 |
Portal vein thrombosis | 48.26 | 22.23 | 26 | 21001 | 5336 | 70902081 |
Hypertensive crisis | 47.55 | 22.23 | 42 | 20985 | 19220 | 70888197 |
Protein urine present | 46.37 | 22.23 | 31 | 20996 | 9409 | 70898008 |
Pneumonitis | 45.86 | 22.23 | 68 | 20959 | 54529 | 70852888 |
Weight decreased | 45.21 | 22.23 | 197 | 20830 | 310291 | 70597126 |
Adrenal insufficiency | 45.13 | 22.23 | 46 | 20981 | 25149 | 70882268 |
Pain | 44.35 | 22.23 | 74 | 20953 | 628742 | 70278675 |
Infusion related reaction | 43.90 | 22.23 | 4 | 21023 | 197530 | 70709887 |
Cerebral infarction | 41.16 | 22.23 | 57 | 20970 | 42952 | 70864465 |
Fall | 40.73 | 22.23 | 43 | 20984 | 444053 | 70463364 |
Immune-mediated hepatic disorder | 40.72 | 22.23 | 14 | 21013 | 954 | 70906463 |
Epistaxis | 40.32 | 22.23 | 92 | 20935 | 102535 | 70804882 |
Product dose omission issue | 39.85 | 22.23 | 8 | 21019 | 217460 | 70689957 |
Sinusitis | 38.76 | 22.23 | 3 | 21024 | 169192 | 70738225 |
Interstitial lung disease | 38.02 | 22.23 | 91 | 20936 | 104594 | 70802823 |
Haemoptysis | 37.47 | 22.23 | 60 | 20967 | 51392 | 70856025 |
Hyponatraemia | 37.06 | 22.23 | 118 | 20909 | 159969 | 70747448 |
Primary adrenal insufficiency | 36.40 | 22.23 | 9 | 21018 | 188 | 70907229 |
Drug intolerance | 36.12 | 22.23 | 11 | 21016 | 225676 | 70681741 |
Upper gastrointestinal haemorrhage | 34.86 | 22.23 | 49 | 20978 | 37428 | 70869989 |
Tumour rupture | 34.69 | 22.23 | 10 | 21017 | 381 | 70907036 |
Abdominal pain | 34.10 | 22.23 | 195 | 20832 | 341932 | 70565485 |
Small intestinal perforation | 34.01 | 22.23 | 17 | 21010 | 2992 | 70904425 |
Tumour lysis syndrome | 32.92 | 22.23 | 36 | 20991 | 21324 | 70886093 |
Joint swelling | 32.90 | 22.23 | 17 | 21010 | 253194 | 70654223 |
Immune-mediated myocarditis | 32.76 | 22.23 | 11 | 21016 | 697 | 70906720 |
Overdose | 31.61 | 22.23 | 6 | 21021 | 169739 | 70737678 |
Arthropathy | 30.89 | 22.23 | 4 | 21023 | 150053 | 70757364 |
Female genital tract fistula | 30.62 | 22.23 | 16 | 21011 | 3087 | 70904330 |
Swelling | 30.51 | 22.23 | 9 | 21018 | 188530 | 70718887 |
Eastern Cooperative Oncology Group performance status worsened | 30.46 | 22.23 | 13 | 21014 | 1595 | 70905822 |
Pulmonary embolism | 29.99 | 22.23 | 108 | 20919 | 155759 | 70751658 |
Treatment failure | 29.29 | 22.23 | 4 | 21023 | 144138 | 70763279 |
Oesophageal perforation | 29.26 | 22.23 | 12 | 21015 | 1332 | 70906085 |
Musculoskeletal stiffness | 27.99 | 22.23 | 5 | 21022 | 147755 | 70759662 |
Insomnia | 27.73 | 22.23 | 15 | 21012 | 217791 | 70689626 |
Rhythm idioventricular | 27.62 | 22.23 | 9 | 21018 | 519 | 70906898 |
Duodenal perforation | 27.49 | 22.23 | 13 | 21014 | 2027 | 70905390 |
Liver disorder | 27.35 | 22.23 | 58 | 20969 | 61510 | 70845907 |
Nasopharyngitis | 27.29 | 22.23 | 16 | 21011 | 222190 | 70685227 |
Depression | 26.38 | 22.23 | 13 | 21014 | 198961 | 70708456 |
Cancer pain | 26.36 | 22.23 | 17 | 21010 | 4857 | 70902560 |
Tracheal haemorrhage | 25.87 | 22.23 | 9 | 21018 | 635 | 70906782 |
Cholangitis acute | 25.47 | 22.23 | 11 | 21016 | 1389 | 70906028 |
Immune-mediated renal disorder | 24.96 | 22.23 | 6 | 21021 | 111 | 70907306 |
Malignant pleural effusion | 24.89 | 22.23 | 14 | 21013 | 3125 | 70904292 |
Injection site pain | 24.53 | 22.23 | 3 | 21024 | 117616 | 70789801 |
Taste disorder | 24.52 | 22.23 | 23 | 21004 | 11362 | 70896055 |
Pancreatitis | 24.40 | 22.23 | 56 | 20971 | 62612 | 70844805 |
Urticaria | 24.25 | 22.23 | 9 | 21018 | 163040 | 70744377 |
Liver abscess | 24.22 | 22.23 | 17 | 21010 | 5582 | 70901835 |
Tumour pain | 24.14 | 22.23 | 12 | 21015 | 2086 | 70905331 |
Oral pain | 24.11 | 22.23 | 36 | 20991 | 29030 | 70878387 |
Peritonitis | 24.02 | 22.23 | 34 | 20993 | 26125 | 70881292 |
Hyperhidrosis | 23.77 | 22.23 | 5 | 21022 | 131581 | 70775836 |
Paraesthesia | 23.45 | 22.23 | 7 | 21020 | 145530 | 70761887 |
Asthma | 23.07 | 22.23 | 4 | 21023 | 120789 | 70786628 |
Hepatic rupture | 22.74 | 22.23 | 5 | 21022 | 61 | 70907356 |
Amylase increased | 22.72 | 22.23 | 21 | 21006 | 10187 | 70897230 |
Pneumonia aspiration | 22.44 | 22.23 | 54 | 20973 | 62235 | 70845182 |
None
Source | Code | Description |
---|---|---|
ATC | L01EX08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors |
FDA MoA | N0000020000 | Receptor Tyrosine Kinase Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:62434 | ALK inhibitor |
CHEBI has role | CHEBI:63457 | FGFR inhibitors |
CHEBI has role | CHEBI:65207 | vascular endothelial growth factor receptor inhibitors |
CHEBI has role | CHEBI:71031 | orphan drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Endometrial carcinoma progressing after chemotherapy | indication | 254878006 | DOID:2871 |
Follicular thyroid carcinoma | indication | 255028004 | DOID:3962 |
Papillary thyroid carcinoma | indication | 255029007 | DOID:3969 |
Renal cell carcinoma | indication | 702391001 | DOID:4450 |
Thymic carcinoma | indication | 722670005 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.09 | acidic |
pKa2 | 12.74 | acidic |
pKa3 | 13.02 | acidic |
pKa4 | 4.67 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | 9006256 | July 27, 2027 | METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | 9006256 | July 27, 2027 | METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Feb. 13, 2022 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Feb. 13, 2022 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Sept. 17, 2022 | TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Sept. 17, 2022 | TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | July 21, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1 |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | July 21, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1 |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 10, 2024 | LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 10, 2024 | LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Dec. 19, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1 |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Dec. 19, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1 |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 15, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 15, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | INHIBITOR | Ki | 8.82 | CHEMBL | DRUG LABEL | |||
Mast/stem cell growth factor receptor Kit | Kinase | INHIBITOR | IC50 | 7 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 7.66 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 2 | Kinase | INHIBITOR | IC50 | 8.40 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 3 | Kinase | INHIBITOR | IC50 | 8.28 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Platelet-derived growth factor receptor alpha | Kinase | INHIBITOR | IC50 | 7.29 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Fibroblast growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 7.34 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Mitogen-activated protein kinase kinase kinase kinase 5 | Kinase | Kd | 5.51 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 7.96 | CHEMBL | |||||
STE20-like serine/threonine-protein kinase | Kinase | Kd | 5.41 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 7.34 | CHEMBL | |||||
Protein-tyrosine kinase 6 | Kinase | Kd | 6.76 | CHEMBL | |||||
MAP kinase-activated protein kinase 2 | Kinase | Kd | 7.20 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 6.66 | CHEMBL | |||||
Aurora kinase B | Kinase | Kd | 5.75 | CHEMBL | |||||
Ribosyldihydronicotinamide dehydrogenase [quinone] | Enzyme | Kd | 5.82 | CHEMBL | |||||
Serine/threonine-protein kinase/endoribonuclease IRE1 | Kinase | Kd | 5.65 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 5.54 | CHEMBL | |||||
Ferrochelatase, mitochondrial | Enzyme | Kd | 5.55 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 3 | Kinase | Kd | 6.50 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 6 | Kinase | Kd | 5.80 | CHEMBL | |||||
Platelet-derived growth factor receptor beta | Kinase | INHIBITOR | IC50 | 7.41 | SCIENTIFIC LITERATURE | ||||
Epidermal growth factor receptor | Kinase | INHIBITOR | IC50 | 5.19 | SCIENTIFIC LITERATURE | ||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 6.24 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | Kd | 5.42 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 6.88 | CHEMBL | |||||
Breakpoint cluster region protein | Kinase | Kd | 5.39 | CHEMBL | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 6.10 | CHEMBL | |||||
TRAF2 and NCK-interacting protein kinase | Kinase | Kd | 6.25 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | Kd | 6.66 | CHEMBL |
ID | Source |
---|---|
EE083865G2 | UNII |
D09919 | KEGG_DRUG |
4034239 | VUID |
N0000191429 | NUI |
857890-39-2 | SECONDARY_CAS_RN |
4034239 | VANDF |
C2986924 | UMLSCUI |
CHEBI:85994 | CHEBI |
LEV | PDB_CHEM_ID |
CHEMBL1289601 | ChEMBL_ID |
9823820 | PUBCHEM_CID |
DB09078 | DRUGBANK_ID |
CHEMBL2105704 | ChEMBL_ID |
9361 | INN_ID |
C531958 | MESH_SUPPLEMENTAL_RECORD_UI |
7426 | IUPHAR_LIGAND_ID |
1603296 | RXNORM |
232716 | MMSL |
294829 | MMSL |
294831 | MMSL |
30895 | MMSL |
d08346 | MMSL |
015899 | NDDF |
015900 | NDDF |
714108002 | SNOMEDCT_US |
714109005 | SNOMEDCT_US |
735068004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-704 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-704 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-704 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-708 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-708 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-708 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-710 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-710 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-710 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-712 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-712 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-712 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-720 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-720 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-720 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |